Unresectable, Locally advanced, Squamous Cell Carcinoma/Skin Cancer Conventional Therapy

Share Button

There is no widely accepted standard-of-care for unresectable, locally advanced, or metastatic Cutaneous Squamous Cell Carcinoma aka Skin Cancer

VIEW
photograph showing close up of squamous cell carcinoma on the skin of a patient's ear
According to research the majority of both basil cell and squamous cell carcinoma cases can be surgically removed with an excellent chance of a complete cure.
If you are reading this blog post it means that you may have been diagnosed with squamous cell skin cancer that cannot be surgically removed and may be locally advanced or metastatic.
 While the article linked and excerpted below documents immunotherapy for unresectable CSCC being “highly responsive” to immunotherapy, the study reported that “Median progression-free survival and overall survival have not been reached.” This means that patients don’t really know immunotherapy’s ability to produce overall survival or progression-free survival.  
photograph showing close up of squamous cell carcinoma on a patient's skinIt’s important to add the importance of evidence-based, non-conventional non-melanoma skin cancer therapies. My point is that if your skin cancer is unresectable and may have metastasized I encourage you to utilize every evidence-based therapy out there at your cancer.
I am a long-term cancer survivor and cancer coach. I have experienced the best and the worst that oncology can offer.  Have you been diagnosed with SCC? Scroll down the page, post a question or a comment and I will reply to you ASAP.
Thank you,
David Emerson
  • Cancer Survivor
  • Cancer Coach
  • Director PeopleBeatingCancer

“A fully human anti–programmed death 1 (PD-1) monoclonal antibody is safe and effective for patients with unresectable, locally advanced, or metastatic cutaneous squamous cell carcinoma (CSCC)

There is no widely accepted standard of care for unresectable, locally advanced, or metastatic CSCC. Conventional chemotherapy can induce tumor response, but often is poorly tolerated among older patients with CSCC…

The most common treatment-related adverse event of any grade was fatigue (19.2%). One grade 3 or higher event was noted for AST elevation, ALT elevation, arthralgia, and rash. Two patients discontinued treatment due to treatment-related adverse events. Two patients died within 30 days of the last dose, but this was considered unrelated to the drug. 

“This is the first prospective study of a PD-1 inhibitor in patients with advanced CSCC. REGN2810 was generally well tolerated in this predominantly older population,” concluded Papadopoulos.

Both locally advanced and metastatic CSCC are highly responsive to the drug, “and durability is emerging,” he said. “A unifying characteristic of cutaneous malignancies appears to be responsiveness to immune checkpoint inhibition.”

 

Leave a Comment: